Retinal Layer Thinning for Monitoring Disease-modifying Treatment in Relapsing Multiple Sclerosis—Evidence for Applying a Rebaselining Concept (P6-6.005)

Gabriel Bsteh; Harald Hegen; Nik Krajnc; Patrick Altmann; Michael Auer; Klaus Berek; Barbara Kornek; Fritz Leutmezer; Stefan Macher; Tobias Monschein; Markus Ponleitner; Paulus Rommer; Christiane Schmied; Karin Zebenholzer; Gudrun Zulehner; Tobias Zrzavy; Florian Deisenhammer; Franziska Di Pauli; Berthold Pemp; Thomas Berger

doi:10.1212/wnl.0000000000204430

Abstract

To investigate whether rebaselining the longitudinal measurement of neuroaxonal damage improves sensitivity for detecting effects of disease-modifying treatment (DMT) in monitoring relapsing multiple sclerosis (RMS).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bsteh et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcc5b6db643587677443 https://doi.org/10.1212/wnl.0000000000204430

View at Publisher

Ask AI

Bookmark

Share

Retinal Layer Thinning for Monitoring Disease-modifying Treatment in Relapsing Multiple Sclerosis—Evidence for Applying a Rebaselining Concept (P6-6.005)

Abstract

Discussion

Cite This Study

Retinal Layer Thinning for Monitoring Disease-modifying Treatment in Relapsing Multiple Sclerosis—Evidence for Applying a Rebaselining Concept (P6-6.005)

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Neurology

Keep reading

More related papers

More from Neurology